Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

被引：0
|
作者：
Scott T. Tagawa
Krishnan Ramaswamy
Ahong Huang
Jack Mardekian
Neil M. Schultz
Li Wang
Rickard Sandin
Stanislav Lechpammer
Daniel J. George
机构：
[1] Weill Cornell Medicine,
[2] Pfizer Inc.,undefined
[3] STATinMED Research,undefined
[4] Astellas Pharma Inc.,undefined
[5] Pfizer AB.,undefined
[6] Pfizer Inc.,undefined
[7] Duke Cancer Institute,undefined
[8] Duke University School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1032 / 1040
页数：8
相关论文
共 50 条
  • [1] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Tagawa, Scott T.
    Ramaswamy, Krishnan
    Huang, Ahong
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Sandin, Rickard
    Lechpammer, Stanislav
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1032 - 1040
  • [2] Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 804 - 804
  • [3] Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 800 - 801
  • [4] Economic Outcomes in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Huang, Ahong
    Schultz, Neil M.
    Sandin, Rickard
    Wang, Li
    Baser, Onur
    George, Daniel J.
    ADVANCES IN THERAPY, 2020, 37 (05) : 2083 - 2097
  • [5] Overall survival by race in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
    McNamara, Megan Ann
    George, Daniel J.
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Baser, Onur
    Huang, Ahong
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Salem, S.
    Komisarenko, M.
    Timilshina, N.
    Martin, L.
    Grewal, R.
    Alibhai, S.
    Finelli, A.
    CLINICAL ONCOLOGY, 2017, 29 (09) : 601 - 608
  • [7] Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
    Matsubara, Nobuaki
    Yamada, Yoko
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    Yano, Akihiro
    Kawakami, Satoru
    Otsuka, Masafumi
    Fukasawa, Satoshi
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 142 - 148
  • [8] Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
    Daniel J. George
    Krishnan Ramaswamy
    Ahong Huang
    David Russell
    Jack Mardekian
    Neil M. Schultz
    Nora Janjan
    Stephen J. Freedland
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 524 - 530
  • [9] Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
    George, Daniel J.
    Ramaswamy, Krishnan
    Huang, Ahong
    Russell, David
    Mardekian, Jack
    Schultz, Neil M.
    Janjan, Nora
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 524 - 530
  • [10] SURVIVAL RATES AND ECONOMIC OUTCOMES IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE OR ENZALUTAMIDE
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Huang, Ahong
    Wang, Li
    Baser, Onur
    George, Daniel
    JOURNAL OF UROLOGY, 2019, 201 (04): : E242 - E243
12345